Last updated 4th January 2022
Covid-age was developed to assist health professionals when advising workers in the UK on their personal vulnerability to COVID-19, and implications for their employment. Vulnerability can be quantified as the probability of death should infection occur. It varies according to age, sex, ethnicity, the presence of other health conditions (comorbidities), and immunity from vaccination or previous infection. Covid-age summarises published evidence on the impacts of age, sex, ethnicity and comorbidities in the absence of vaccination or previous infection. It is intended for use as part of occupational health assessment of individuals’ fitness for work, and not in clinical treatment pathways.
WHAT DOES COVID-AGE MEAN?
An individual’s Covid-age is calculated by expressing the impacts of risk factors as added years of age that would carry a similar increase in vulnerability. The values for each applicable risk factor are then added to the individual’s true age. This gives an estimate of the age of a healthy white man, who in the absence of vaccination or previous infection, would be expected to have similar vulnerability.
HOW SHOULD COVID-AGE BE USED?
When assessing a worker’s occupational risk from COVID-19, their Covid-age can be set alongside their history of vaccination and/or infection to derive an overall estimate of personal vulnerability. That assessment can then be combined with knowledge about their job and the expected community prevalence of infection, to obtain an assessment of risk (for more detailed guidance, see section below on Management of occupational risks from COVID-19).
HOW DO I FIND A PERSON’S COVID-AGE?
The easy way is to enter risk factors into the online calculator below.
Alternatively, you can calculate Covid-age using Table 1 at the bottom of this page (see section below on Estimating Covid-age using tables).
Before using Covid-age, it is important to note the following caveats.
CAVEATS
Because each individual is different, Covid-age is not an exact measure of vulnerability. It is an estimate consistent with the current balance of scientific evidence.
Some of the categories of comorbidity are broad-ranging, and within them, vulnerability may vary. The tool gives an overall average estimate of vulnerability, which may be individually tailored through clinical judgement of a suitably qualified health professional.
Some potentially relevant health problems are not covered by the tool, because insufficient evidence is available on them. Using clinical judgement, it may in some cases be reasonable to apply added years that have been estimated for another similar condition. For example, there is evidence that inflammatory bowel diseases and inflammatory skin diseases carry similar vulnerability to inflammatory joint diseases.
Covid-age does not assess risks from Covid-19 in pregnancy. While there is evidence of increased vulnerability during pregnancy, it is not in a form that can be incorporated into the current risk model. Moreover, the disease can impact adversely on obstetric outcomes as well as maternal health. When assessing and managing occupational risks from Covid-19 during pregnancy, users should refer to https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/covid-19-virus-infection-and-pregnancy/
Covid-age is based on evidence relating to various comorbidities, but in most cases, their treatment has not been considered separately. The estimate of added years for a condition represents an average across the spectrum of treatment for that disease. This includes the effects of treatment with immunosuppressive medication, and it is not necessary to add further years of age in respect of such treatment.
The group ‘other immunosuppressive disorders’ refers to medical conditions that depress immune responses, and which are not included elsewhere in the calculator. It does not cover immunosuppressive medication. Any immunological effects of diseases that are listed elsewhere in the calculator (e.g. diabetes, splenectomy) are covered by those categories.
Calculations assume as a default that added years for different risk factors can be summed (i.e. that relative risks multiply). However, that assumption may not be accurate for all risk factors, especially when it leads to calculated Covid-ages greater than 85. The online calculator therefore presents Covid-ages in this upper range simply as >85. It does, however, show the years added for each risk factor so that clinicians can see the assumed impact of different conditions.
SOURCES OF EVIDENCE ON VULNERABILITY
Further details of the background evidence and methods can be found here: Methods at 211214
MANAGEMENT OF OCCUPATIONAL RISKS FROM COVID-19
CONTEXT
In managing occupational risks of Covid-19, employers must control exposure to the virus so far as is reasonably practicable, taking into account the possibility that some workers will be more vulnerable than others should they contract the disease.
Strategies may include changes to the way in which work is carried out, use of barriers and personal protective equipment (PPE), and in some cases, exclusion or redeployment of individuals who are more vulnerable. The need for selective exclusion/redeployment of vulnerable workers will depend on the likelihood of their contracting Covid-19 through their work, and on the extent of their personal vulnerability to severe illness should they get the disease.
The level of individual risk that is considered acceptable will depend on value judgements, which can differ from person to person, and it is therefore not possible to lay down hard and fast rules. However, we here suggest an approach that may be a useful starting point for decision-making.
The approach entails first using Covid-age to assess the individual’s vulnerability to COVID-19 in the absence of previous infection or vaccination. That assessment is then modified to account for any previous infection or vaccination. Finally, a matrix is applied to guide decisions according to the nature of the job and local prevalence of infection.
VULNERABILITY LEVELS
It may be convenient to stratify vulnerability into ranges. We have used a lower bound of Covid-age 85 to define a stratum of ‘very high vulnerability’. In the absence of vaccination or previous infection, this may correspond to infection fatality rates in excess of around one in twenty, and could be considered equivalent to being ‘clinically extremely vulnerable’.
To define a second stratum of ‘high vulnerability’, we suggest a lower bound at Covid-age 70 (which in those with no vaccination or previous infection has carried an infection fatality rate of around one in a hundred). This corresponds approximately to the threshold for the Government’s category of ‘clinically vulnerable’.
To account for differences in vulnerability below that level, we suggest a further cut-point at Covid-age 50, which distinguishes ‘moderate vulnerability’ from ‘low vulnerability’.
Covid-age will determine the stratum of vulnerability to which an individual is initially assigned, but in some cases clinical judgement may indicate that a different stratum is appropriate because of individual circumstances.
ACCOUNTING FOR SPECIFIC IMMUNITY
Specific immunity from previous infection and/or vaccination may reduce both the risk of becoming infected by SARS-CoV-2 and personal vulnerability should infection occur. The level of protection will vary according to time interval(s) since infection/vaccination, number of vaccinations, type(s) of vaccine administered, and the variant(s) of the virus to which the individual is subsequently exposed. It may also differ in the presence of comorbidities, and particularly those which impair immune responses.
Currently available data do not allow detailed quantitative assessment of how reductions in risk differ according to these variables, or how they are apportioned between lower rates of infection and lower vulnerability once infection has occurred. It appears, however, that on average among people of working age, previous infection or vaccination will provide protection in excess of 80% against mortality from variants of SARS-CoV-2 that are currently dominant in the UK. Moreover, that protection will last for months or longer, and can be enhanced by further vaccination.
The table below shows relative risks corresponding to different levels of vaccine protection against death from Covid-19, and reductions in Covid-age that would give an equivalent reduction in risk.
Level of vaccine protection (%) against death from Covid-19 | Relative risk of death from Covid-19 | Reduction in Covid-age (years) that would give equivalent relative risk |
97.5 | 0.025 | 36 |
95 | 0.05 | 29 |
90 | 0.1 | 22 |
85 | 0.15 | 18 |
80 | 0.2 | 16 |
75 | 0.25 | 13 |
70 | 0.3 | 12 |
65 | 0.35 | 10 |
60 | 0.4 | 9 |
50 | 0.5 | 7 |
40 | 0.6 | 5 |
30 | 0.7 | 3 |
We suggest that to account for reduced risk from vaccination, it would be reasonable in many cases to shift a previously infected/vaccinated individual down by one stratum of vulnerability – for example, from ‘very high’ to ‘high’ or from ‘high’ to ‘moderate’.
An exception might be individuals on immune suppressant medication or with conditions affecting immunity such as HIV or cancer, who may not respond so well to vaccines. Particularly in such cases, clinical judgement should be applied when considering adjustments to assessed vulnerability.
ACCOUNTING FOR VIRAL PREVALENCE
A major determinant of risk is local prevalence of infection by SARS-CoV-2, Other things being equal, in occupations that do not involve selective contact with people more likely to be carrying the virus (as occurs for example in healthcare), risk of exposure can be expected to vary in proportion to the local prevalence of infection.
A MATRIX FOR RISK MANAGEMENT
Based on the above considerations, we set out below a matrix combining what we know about vulnerability, immunity, and viral prevalence to classify individuals according to the type of work that they might reasonably undertake. It should be viewed as a rough guide and tailored to account for special circumstances and the views of the worker.
Matrix guide for estimation of a worker’s overall risk pre-and post-vaccination
Overall risk is very high, avoid this activity | |
Overall risk is high, only undertake this activity if it is essential and cannot be avoided | |
Overall risk is moderate, avoid if the activity is unnecessary | |
Overall risk is low, no requirement for any additional adjustments or controls |
70-84
Viral prevalence per weekα | |||||
---|---|---|---|---|---|
Workplace risk | Covid-age Adjusted for immunity | 1-9/100,000 | 10-99/100,000 | 100-999/100,000 | 1000+/100,000 |
Very High In rooms, wards or vehicles caring for Covid-positive patients where full PPE cannot be worn reliably. | 85 & above | ||||
70-84 | |||||
50-69 | |||||
Under 50 | |||||
High In rooms, wards, accommodation buildings or vehicles in close proximity to people with suspected Covid-19. | 85 & above | ||||
70-84 | |||||
50-69 | |||||
Under 50 | |||||
Medium High number of different face-to-face contacts. e.g. healthcare, care homes, social care, hairdressing, teaching, police, probation work, supermarket staff. Public transport staff and passengers | 85 & above | ||||
70-84 | |||||
50-69 | |||||
Under 50 | |||||
Low Good social distancing, ventilation and hygiene measures e.g. call centre work, office work, in-home utility and repair work. Commuting by car, bicycle and walking. | 85 & above | ||||
70-84 | |||||
50-69 | |||||
Under 50 | |||||
Working from home | All ages |
αIndividual Government websites provide current viral prevalence rates, although this can also be accessed via: https://www.bbc.co.uk/news/uk-51768274
A guide to using this matrix can also be downloaded from
ESTIMATING COVID-AGE USING TABLES
Use these tables by starting with the person’s actual age and then adding or subtracting years for each risk factor that applies, using Table 1 below.
First find their actual age in the top line of the table, then follow the column down to find the estimated impact (i.e. years to add or subtract from their actual age) for each risk factor that applies to that person. For example:
- A healthy white woman, aged 40, has a Covid-age of (40-5) = 35 years
- A white man aged 45, BMI 36 with severe asthma, has a Covid-age of (45+13+11) = 69 years.
- An Asian woman aged 50 with Type 2 diabetes, unknown HbA1c, has a Covid-age of (50-5+5+20) = 70 years.
Whether a person’s Covid-age is obtained from the online calculator or using Table 1, minor modification may be warranted to account for the specific circumstances of the individual (e.g. the severity of relevant comorbidities). If you judge that to be appropriate, you should make the adjustment using your clinical judgement,
Table 1. Vulnerability from risk factors expressed as equivalence to added years of age
True age (years) | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||||||
30-34.9 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 |
35-39.9 | 19 | 19 | 19 | 18 | 18 | 18 | 18 | 17 | 17 | 17 |
≥40 | 25 | 25 | 24 | 24 | 24 | 23 | 23 | 23 | 22 | 22 |
Hypertension | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 11 | 11 | 11 |
Heart failure | 25 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 24 |
Other chronic heart disease | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 |
Cerebrovascular disease | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Asthma | ||||||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 15 | 15 | 15 | 15 | 15 | 15 | 14 | 14 | 14 | 14 |
Other chronic respiratory disease | 17 | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 |
Diabetes | ||||||||||
Type 1 | ||||||||||
HbA1≤58 mmol/mol in past year | 24 | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 23 |
HbA1>58 mmol/mol in past year | 27 | 27 | 27 | 27 | 27 | 27 | 26 | 26 | 26 | 26 |
HbA1c unknown | 29 | 29 | 29 | 29 | 29 | 28 | 28 | 28 | 28 | 28 |
Type 2 and other | ||||||||||
HbA1≤58 mmol/mol in past year | 21 | 21 | 21 | 21 | 21 | 20 | 20 | 20 | 20 | 20 |
HbA1>58 mmol/mol in past year | 23 | 23 | 23 | 23 | 23 | 22 | 22 | 22 | 22 | 22 |
HbA1c unknown | 22 | 22 | 22 | 22 | 22 | 21 | 21 | 21 | 21 | 21 |
Chronic kidney disease | ||||||||||
Estimated GFR 30-60 mL/min | 42 | 41 | 40 | 39 | 38 | 37 | 37 | 36 | 35 | 34 |
Estimated GFR < 30 mL/min | 53 | 52 | 51 | 50 | 50 | 49 | 48 | 47 | 46 | 46 |
Non-haematological cancer | ||||||||||
Diagnosed <1 year ago | 34 | 33 | 33 | 32 | 32 | 31 | 31 | 30 | 30 | 29 |
Diagnosed 1-4.9 years ago | 25 | 25 | 25 | 24 | 24 | 24 | 23 | 23 | 22 | 22 |
Diagnosed ≥5 years ago | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 16 | 16 | 16 |
Haematological malignancy | ||||||||||
Diagnosed <1 year ago | 33 | 33 | 32 | 32 | 32 | 32 | 31 | 31 | 31 | 31 |
Diagnosed 1-4.9 years ago | 32 | 31 | 31 | 31 | 30 | 30 | 30 | 29 | 29 | 29 |
Diagnosed ≥5 years ago | 21 | 21 | 21 | 21 | 21 | 20 | 20 | 20 | 20 | 20 |
Liver disease | 32 | 31 | 31 | 30 | 30 | 29 | 29 | 28 | 28 | 27 |
Chronic neurological disease other than stroke or dementia* | 23 | 23 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Organ transplant | 25 | 25 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Spleen diseases† | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 30 | 30 | 29 | 29 | 28 | 28 | 27 | 27 | 26 | 26 |
True age (years) | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||||||
30-34.9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 |
35-39.9 | 17 | 16 | 16 | 16 | 16 | 15 | 15 | 15 | 15 | 15 |
≥40 | 22 | 21 | 21 | 21 | 20 | 20 | 19 | 19 | 19 | 18 |
Hypertension | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 |
Heart failure | 24 | 23 | 23 | 23 | 22 | 22 | 22 | 22 | 21 | 21 |
Other chronic heart disease | 19 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 | 16 |
Cerebrovascular disease | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 15 | 15 | 15 |
Asthma | ||||||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 12 | 12 |
Other chronic respiratory disease | 16 | 15 | 15 | 15 | 15 | 15 | 14 | 14 | 14 | 14 |
Diabetes | ||||||||||
Type 1 | ||||||||||
HbA1≤58 mmol/mol in past year | 23 | 23 | 22 | 22 | 22 | 22 | 22 | 21 | 21 | 21 |
HbA1>58 mmol/mol in past year | 26 | 26 | 25 | 25 | 25 | 25 | 25 | 25 | 24 | 24 |
HbA1c unknown | 28 | 28 | 28 | 27 | 27 | 27 | 27 | 27 | 26 | 26 |
Type 2 and other | ||||||||||
HbA1≤58 mmol/mol in past year | 20 | 20 | 20 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
HbA1>58 mmol/mol in past year | 22 | 22 | 22 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
HbA1c unknown | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 20 |
Chronic kidney disease | ||||||||||
Estimated GFR 30-60 mL/min | 33 | 32 | 32 | 31 | 30 | 29 | 28 | 27 | 26 | 26 |
Estimated GFR < 30 mL/min | 45 | 44 | 44 | 43 | 42 | 41 | 40 | 39 | 38 | 37 |
Non-haematological cancer | ||||||||||
Diagnosed <1 year ago | 29 | 28 | 28 | 27 | 27 | 26 | 26 | 25 | 25 | 24 |
Diagnosed 1-4.9 years ago | 22 | 21 | 21 | 21 | 20 | 20 | 19 | 19 | 18 | 18 |
Diagnosed ≥5 years ago | 15 | 15 | 15 | 14 | 14 | 13 | 13 | 12 | 12 | 11 |
Haematological malignancy | ||||||||||
Diagnosed <1 year ago | 30 | 30 | 30 | 30 | 29 | 29 | 29 | 29 | 28 | 28 |
Diagnosed 1-4.9 years ago | 28 | 28 | 28 | 27 | 27 | 27 | 26 | 26 | 25 | 25 |
Diagnosed ≥5 years ago | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 18 | 17 |
Liver disease | 27 | 26 | 26 | 25 | 25 | 24 | 24 | 23 | 23 | 22 |
Chronic neurological disease other than stroke or dementia* | 22 | 22 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 20 |
Organ transplant | 23 | 23 | 23 | 23 | 23 | 23 | 22 | 22 | 22 | 22 |
Spleen diseases† | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 25 | 25 | 24 | 24 | 23 | 23 | 22 | 22 | 21 | 21 |
True age (years) | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||||||
30-34.9 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 |
35-39.9 | 14 | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 12 | 12 |
≥40 | 18 | 17 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 |
Hypertension | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 |
Heart failure | 21 | 20 | 20 | 20 | 19 | 19 | 19 | 18 | 18 | 18 |
Other chronic heart disease | 16 | 15 | 15 | 15 | 14 | 14 | 14 | 13 | 13 | 13 |
Cerebrovascular disease | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 14 | 14 | 14 |
Asthma | ||||||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 12 | 12 | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 |
Other chronic respiratory disease | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 |
Diabetes | ||||||||||
Type 1 | ||||||||||
HbA1≤58 mmol/mol in past year | 21 | 21 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 18 |
HbA1>58 mmol/mol in past year | 24 | 24 | 24 | 23 | 23 | 23 | 23 | 22 | 22 | 22 |
HbA1c unknown | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 23 |
Type 2 and other | ||||||||||
HbA1≤58 mmol/mol in past year | 19 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 16 |
HbA1>58 mmol/mol in past year | 21 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 18 |
HbA1c unknown | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 18 |
Chronic kidney disease | ||||||||||
Estimated GFR 30-60 mL/min | 25 | 24 | 23 | 22 | 21 | 20 | 19 | 19 | 18 | 18 |
Estimated GFR < 30 mL/min | 36 | 35 | 35 | 34 | 33 | 33 | 32 | 32 | 31 | 30 |
Non-haematological cancer | ||||||||||
Diagnosed <1 year ago | 24 | 23 | 23 | 22 | 22 | 21 | 21 | 20 | 20 | 19 |
Diagnosed 1-4.9 years ago | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 | 13 |
Diagnosed ≥5 years ago | 11 | 11 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 8 |
Haematological malignancy | ||||||||||
Diagnosed <1 year ago | 28 | 28 | 27 | 27 | 27 | 26 | 26 | 26 | 25 | 25 |
Diagnosed 1-4.9 years ago | 25 | 24 | 24 | 23 | 23 | 22 | 22 | 22 | 22 | 22 |
Diagnosed ≥5 years ago | 17 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 | 14 |
Liver disease | 22 | 21 | 21 | 20 | 20 | 19 | 19 | 18 | 17 | 17 |
Chronic neurological disease other than stroke or dementia* | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 |
Organ transplant | 22 | 22 | 21 | 21 | 21 | 21 | 21 | 20 | 20 | 20 |
Spleen diseases† | 11 | 11 | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 10 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 20 | 20 | 19 | 19 | 18 | 17 | 17 | 16 | 16 | 15 |
True age (years) | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||||||
30-34.9 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
35-39.9 | 12 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 9 | 9 |
≥40 | 14 | 14 | 13 | 13 | 12 | 12 | 12 | 11 | 11 | 11 |
Hypertension | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 |
Heart failure | 17 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 | 14 |
Other chronic heart disease | 13 | 12 | 12 | 12 | 12 | 11 | 11 | 10 | 10 | 9 |
Cerebrovascular disease | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 12 | 12 |
Asthma | ||||||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 7 | 7 | 7 |
Other chronic respiratory disease | 12 | 12 | 11 | 11 | 11 | 11 | 10 | 10 | 10 | 9 |
Diabetes | ||||||||||
Type 1 | ||||||||||
HbA1≤58 mmol/mol in past year | 18 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 |
HbA1>58 mmol/mol in past year | 21 | 21 | 20 | 20 | 19 | 19 | 19 | 18 | 18 | 17 |
HbA1c unknown | 23 | 23 | 22 | 22 | 21 | 21 | 20 | 20 | 19 | 19 |
Type 2 and other | ||||||||||
HbA1≤58 mmol/mol in past year | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 13 | 13 | 12 |
HbA1>58 mmol/mol in past year | 18 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 |
HbA1c unknown | 18 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 14 |
Chronic kidney disease | ||||||||||
Estimated GFR 30-60 mL/min | 17 | 16 | 16 | 15 | 14 | 14 | 13 | 13 | 12 | 11 |
Estimated GFR < 30 mL/min | 30 | 29 | 28 | 28 | 27 | 26 | 26 | 25 | 24 | 23 |
Non-haematological cancer | ||||||||||
Diagnosed <1 year ago | 19 | 18 | 18 | 17 | 16 | 16 | 15 | 15 | 14 | 14 |
Diagnosed 1-4.9 years ago | 13 | 12 | 11 | 11 | 10 | 10 | 9 | 9 | 8 | 8 |
Diagnosed ≥5 years ago | 8 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 4 |
Haematological malignancy | ||||||||||
Diagnosed <1 year ago | 24 | 24 | 23 | 23 | 22 | 22 | 21 | 21 | 20 | 20 |
Diagnosed 1-4.9 years ago | 21 | 21 | 21 | 21 | 20 | 20 | 20 | 19 | 19 | 18 |
Diagnosed ≥5 years ago | 13 | 12 | 12 | 11 | 11 | 10 | 10 | 10 | 9 | 9 |
Liver disease | 16 | 15 | 15 | 14 | 14 | 13 | 13 | 12 | 12 | 11 |
Chronic neurological disease other than stroke or dementia* | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 16 | 16 | 16 |
Organ transplant | 19 | 19 | 19 | 18 | 18 | 18 | 17 | 17 | 16 | 16 |
Spleen diseases† | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 12 | 12 | 11 |
True age (years) | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||||||
30-34.9 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
35-39.9 | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 6 | 6 | 5 |
≥40 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 8 | 7 | 7 |
Hypertension | 5 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 2 | 2 |
Heart failure | 13 | 13 | 12 | 12 | 11 | 11 | 11 | 10 | 10 | 10 |
Other chronic heart disease | 9 | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 |
Cerebrovascular disease | 12 | 12 | 12 | 11 | 11 | 11 | 11 | 11 | 10 | 10 |
Asthma | ||||||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 6 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 3 | 3 |
Other chronic respiratory disease | 9 | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 |
Diabetes | ||||||||||
Type 1 | ||||||||||
HbA1≤58 mmol/mol in past year | 14 | 13 | 13 | 12 | 12 | 11 | 11 | 11 | 10 | 10 |
HbA1>58 mmol/mol in past year | 17 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 13 | 13 |
HbA1c unknown | 18 | 18 | 17 | 17 | 16 | 16 | 15 | 15 | 14 | 14 |
Type 2 and other | ||||||||||
HbA1≤58 mmol/mol in past year | 12 | 11 | 11 | 10 | 10 | 9 | 9 | 8 | 8 | 7 |
HbA1>58 mmol/mol in past year | 14 | 13 | 13 | 12 | 12 | 11 | 11 | 11 | 10 | 10 |
HbA1c unknown | 14 | 13 | 13 | 12 | 12 | 11 | 11 | 11 | 10 | 10 |
Chronic kidney disease | ||||||||||
Estimated GFR 30-60 mL/min | 11 | 10 | 9 | 9 | 8 | 8 | 7 | 7 | 6 | 6 |
Estimated GFR < 30 mL/min | 23 | 22 | 22 | 21 | 20 | 20 | 19 | 19 | 18 | 18 |
Non-haematological cancer | ||||||||||
Diagnosed <1 year ago | 13 | 13 | 12 | 12 | 11 | 11 | 10 | 10 | 9 | 9 |
Diagnosed 1-4.9 years ago | 8 | 7 | 7 | 7 | 6 | 6 | 6 | 5 | 5 | 4 |
Diagnosed ≥5 years ago | 4 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
Haematological malignancy | ||||||||||
Diagnosed <1 year ago | 19 | 19 | 18 | 17 | 17 | 16 | 16 | 15 | 15 | 14 |
Diagnosed 1-4.9 years ago | 18 | 17 | 17 | 16 | 16 | 15 | 15 | 14 | 14 | 13 |
Diagnosed ≥5 years ago | 9 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 |
Liver disease | 11 | 10 | 10 | 9 | 9 | 8 | 8 | 7 | 7 | 6 |
Chronic neurological disease other than stroke or dementia* | 16 | 15 | 15 | 15 | 14 | 14 | 14 | 14 | 13 | 13 |
Organ transplant | 15 | 15 | 14 | 14 | 13 | 13 | 12 | 12 | 11 | 11 |
Spleen diseases† | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 3 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 11 | 11 | 10 | 10 | 9 | 9 | 9 | 8 | 8 | 7 |
True age (years) | 70 | 71 | 72 | 73 | 74 | 75 |
Female sex | -5 | -5 | -5 | -5 | -5 | -5 |
Ethnicity | ||||||
Asian or Asian British | 5 | 5 | 5 | 5 | 5 | 5 |
Black | 7 | 7 | 7 | 7 | 7 | 7 |
Mixed | 5 | 5 | 5 | 5 | 5 | 5 |
Other non-white | 4 | 4 | 4 | 4 | 4 | 4 |
Body mass index (Kg/m2) | ||||||
30-34.9 | 2 | 1 | 1 | 1 | 1 | 1 |
35-39.9 | 5 | 5 | 4 | 4 | 3 | 3 |
≥40 | 7 | 6 | 6 | 5 | 5 | 5 |
Hypertension | 2 | 1 | 1 | 0 | 0 | 0 |
Heart failure | 9 | 9 | 9 | 8 | 8 | 8 |
Other chronic heart disease | 4 | 4 | 4 | 3 | 3 | 3 |
Cerebrovascular disease | 10 | 10 | 9 | 9 | 9 | 9 |
Asthma | ||||||
Mild | 1 | 1 | 1 | 1 | 1 | 1 |
Severe | 3 | 3 | 2 | 2 | 2 | 2 |
Other chronic respiratory disease | 6 | 6 | 6 | 6 | 6 | 6 |
Diabetes | ||||||
Type 1 | ||||||
HbA1≤58 mmol/mol in past year | 10 | 9 | 9 | 8 | 8 | 8 |
HbA1>58 mmol/mol in past year | 13 | 12 | 12 | 12 | 11 | 11 |
HbA1c unknown | 14 | 13 | 13 | 12 | 12 | 12 |
Type 2 and other | ||||||
HbA1≤58 mmol/mol in past year | 7 | 6 | 6 | 6 | 5 | 5 |
HbA1>58 mmol/mol in past year | 9 | 9 | 9 | 8 | 8 | 8 |
HbA1c unknown | 9 | 9 | 9 | 8 | 8 | 7 |
Chronic kidney disease | ||||||
Estimated GFR 30-60 mL/min | 5 | 5 | 4 | 4 | 3 | 3 |
Estimated GFR < 30 mL/min | 17 | 17 | 16 | 16 | 15 | 15 |
Non-haematological cancer | ||||||
Diagnosed <1 year ago | 9 | 8 | 8 | 8 | 7 | 7 |
Diagnosed 1-4.9 years ago | 4 | 3 | 3 | 3 | 2 | 2 |
Diagnosed ≥5 years ago | 0 | 0 | 0 | 0 | 0 | 0 |
Haematological malignancy | ||||||
Diagnosed <1 year ago | 14 | 13 | 13 | 12 | 12 | 11 |
Diagnosed 1-4.9 years ago | 13 | 12 | 12 | 11 | 11 | 11 |
Diagnosed ≥5 years ago | 6 | 6 | 5 | 5 | 5 | 5 |
Liver disease | 6 | 6 | 5 | 5 | 4 | 4 |
Chronic neurological disease other than stroke or dementia* | 13 | 13 | 12 | 12 | 12 | 12 |
Organ transplant | 10 | 10 | 9 | 9 | 8 | 8 |
Spleen diseases† | 3 | 2 | 2 | 1 | 1 | 0 |
Rheumatoid/lupus/psoriasis | 2 | 2 | 2 | 2 | 2 | 2 |
Other immunosuppressive condition‡ | 7 | 7 | 6 | 6 | 5 | 5 |
*Chronic neurological disease other than stroke or dementia includes motor neurone disease, myasthenia gravis, multiple sclerosis, Parkinson’s disease, cerebral palsy, quadriplegia, hemiplegia and progressive cerebellar disease.
†Spleen diseases include splenectomy, or spleen dysfunction (e.g. from sickle cell disease).
‡Other immunosuppressive condition includes HIV, conditions inducing permanent immunodeficiency (ever diagnosed), aplastic anaemia, and temporary immunodeficiency recorded within the past year.
PROJECT PARTICIPANTS
The work has been undertaken by the Joint Occupational Health COVID-19 Group:
Principal Authors:
Prof David Coggon, Southampton, Prof Peter Croft, Keele, Prof Paul Cullinan, Imperial College London, Dr Tony Williams, Working Fit Ltd
OpenSAFELY team:
Our thanks to the OpenSAFELY team, and in particular to Prof Krishnan Bhaskharan, Professor of Statistical Epidemiology at the London School of Hygiene and Tropical Medicine, for providing the additional analyses used in the update of the Covid Age tables and Dr Elizabeth Williamson, Associate Professor of Medical Statistics at the London School of Hygiene and Tropical Medicine. These analyses are open access and can be found, with all other OpenSafely publications, athttps://opensafely.org/research/
Website calculator:
Our thanks to Dr David Hodkin for developing the calculator, and for RStudio for hosting the tool on their shinyapps.io cloud.
Excel calculator:
Our thanks to Dr Mark Glover and Lalji Varsani for developing the Excel calculators.
Strategy Group:
Prof Ewan MacDonald, Glasgow (Chair), Prof Raymond Agius, Manchester, Prof Mike Pearson, Liverpool, Dr Anne de Bono, Faculty of Occupational Medicine, Dr Will Ponsonby, Society of Occupational Medicine, Dr Blandina Blackburn, NHS Health at Work Network, Dr Alastair Leckie, NHS Lothian, Dr Drushca Lalloo, Glasgow, Dr Munna Roy, Glasgow, Dr Clare Rayner, Manchester
Working Group for Tables:
Dr Jacqui Bollman, Dr Pam Collins, Dr Andrew Dickson, Dr Emma McCollum, Dr Kerry McNeil, Dr Pam Mellors, Dr Peter Noone, Dr Chris Valentine, Dr Eugene Waclawski, Dr Tony Williams
Project Manager:
Dr Tony Williams, Working Fit Ltd
covid19@workingfit.com
Pregnancy and COVID-19